 |
26 Diseases |  |
30 Trials |
|
30 Trials |  |
518 News |  |
| «12345678910111213» |
- ||| Trial initiation date: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=85, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| ETBX-061 / ImmunityBio, NK92-CD16-158V / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=80, Recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment closed, Trial primary completion date: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=61, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Initiation date: Aug 2017 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Metastases: IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer (clinicaltrials.gov) - Oct 24, 2017
P1, N=28, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- | CST-101 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment closed, Combination therapy, Metastases: QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) (clinicaltrials.gov) - Oct 23, 2017
P2, N=24, Active, not recruiting, Sponsor: NantKwest, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Checkpoint inhibition, MSi-H Biomarker, PD(L)-1 Biomarker: QUILT-3.055: a Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (clinicaltrials.gov) - Oct 23, 2017
P2b, N=105, Recruiting, Sponsor: Altor BioScience
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - Oct 7, 2017
P2, N=60, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2020 --> Nov 2020
- ETBX-011 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment closed, Enrollment change, Combination therapy: QUILT-3.040t: QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer (clinicaltrials.gov) - Oct 5, 2017
P1b/2, N=3, Active, not recruiting, Sponsor: NantCell, Inc.
Trial primary completion date: Apr 2020 --> Nov 2020 Recruiting --> Active, not recruiting | N=150 --> 3
- |||| ETBX-011 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Combination therapy: QUILT-3.040t: QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer (clinicaltrials.gov) - Sep 18, 2017
P1b/2, N=150, Recruiting, Sponsor: NantCell, Inc.
Recruiting --> Active, not recruiting | N=150 --> 3 Not yet recruiting --> Recruiting
- |||| Enrollment open, Trial initiation date: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Aug 25, 2017
P1/2, N=80, Recruiting, Sponsor: NantCell, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Aug 2017
- | Anktiva (inbakicept) / ImmunityBio
Journal: IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. (Pubmed Central) - Jul 19, 2017
ALT-803 enhances NK cell cytotoxicity against ovarian cancer in vitro and in vivo and is able to rescue functionality of NK cells derived from ovarian cancer patient ascites. These findings suggest that ALT-803 has the potential to enhance NK cell-based immunotherapeutic approaches for the treatment of ovarian cancer.
- ||||| New P1/2 trial: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Jun 22, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (clinicaltrials.gov) - Jun 22, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantCell, Inc.
- | Anktiva (inbakicept) / NantWorks
Journal: Intravesical ALT-803 for BCG-unresponsive Bladder Cancer - A Case Report. (Pubmed Central) - Jun 15, 2017
Thus better therapeutic strategies are needed for patients who have failed intravesical therapy. In this article, we report the treatment of a 91-year-old man with NMIBC with high-risk features that had failed multiple intravesical therapies.
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date, Metastases: IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer (clinicaltrials.gov) - Jun 14, 2017
P1, N=28, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
In this article, we report the treatment of a 91-year-old man with NMIBC with high-risk features that had failed multiple intravesical therapies. Initiation date: May 2017 --> Aug 2017
- |||||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Combination therapy: QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Jun 7, 2017
P2/3, N=100, Recruiting, Sponsor: Altor Bioscience Corporation
Initiation date: May 2017 --> Aug 2017 Not yet recruiting --> Recruiting
- ||||| New P1/2 trial: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (clinicaltrials.gov) - Jun 5, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (clinicaltrials.gov) - May 30, 2017
P1/2, N=85, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - May 30, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (clinicaltrials.gov) - May 30, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| ETBX-061 / ImmunityBio, NK92-CD16-158V / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1/2 trial: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (clinicaltrials.gov) - May 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantCell, Inc.
- | Anktiva (inbakicept) / NantWorks
Journal: A novel fusion of ALT-803 (IL-15 Superagonist) with an antibody demonstrates antigen-specific antitumor responses. (Pubmed Central) - May 27, 2017
When compared to rituximab, 2B8T2M exhibits significantly stronger antitumor activity in a xenograft SCID mouse model and depletes B cells in cynomolgus monkeys more efficiently. Thus, ALT-803 can be modified as a functional scaffold for creating multi-specific, IL-15-based immunotherapeutics and may serve as a novel platform to improve antitumor activity and clinical efficacy of therapeutic antibodies.
- ||||| New P1/2 trial: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (clinicaltrials.gov) - May 25, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - May 25, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantCell, Inc.
- | CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - May 19, 2017
P1/2, N=48, Recruiting, Sponsor: Washington University School of Medicine
Thus, ALT-803 can be modified as a functional scaffold for creating multi-specific, IL-15-based immunotherapeutics and may serve as a novel platform to improve antitumor activity and clinical efficacy of therapeutic antibodies. Trial primary completion date: Sep 2017 --> Dec 2020
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open: QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML (clinicaltrials.gov) - May 18, 2017
P2, N=24, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Sep 2017 --> Dec 2020 Not yet recruiting --> Recruiting
- | CIML NK cells / Washington University School of Medicine in St. Louis
Phase classification, Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - May 12, 2017
P1/2, N=48, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Phase classification: P1 --> P1/2 | Trial primary completion date: Mar 2017 --> Sep 2017
- Empliciti (elotuzumab) / AbbVie, BMS
Trial initiation date: 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) (clinicaltrials.gov) - May 9, 2017
P2, N=10, Not yet recruiting, Sponsor: University of Arkansas
Phase classification: P1 --> P1/2 | Trial primary completion date: Mar 2017 --> Sep 2017 Initiation date: Apr 2017 --> Jul 2017
- ||||| New P1/2 trial: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - May 1, 2017
P1/2, N=80, Not yet recruiting, Sponsor: NantCell, Inc.
- | Anktiva (inbakicept) / ImmunityBio
Trial primary completion date: ALT-803: Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People (clinicaltrials.gov) - Apr 20, 2017
P1, N=10, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Initiation date: Apr 2017 --> Jul 2017 Trial primary completion date: Mar 2017 --> Dec 2017
- ||||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment change, Combination therapy: QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Apr 17, 2017
P2/3, N=100, Not yet recruiting, Sponsor: Altor Bioscience Corporation
Trial primary completion date: Mar 2017 --> Dec 2017 N=80 --> 100
- | Anktiva (inbakicept) / ImmunityBio
Enrollment open: Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT (clinicaltrials.gov) - Apr 16, 2017
P2, N=60, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=80 --> 100 Not yet recruiting --> Recruiting
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment change, Trial initiation date, Combination therapy: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (clinicaltrials.gov) - Apr 4, 2017
P1, N=54, Not yet recruiting, Sponsor: David Wald
Not yet recruiting --> Recruiting N=27 --> 54 | Initiation date: Oct 2016 --> May 2017
- || Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial primary completion date, IO biomarker: QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 14, 2017
P1/2, N=57, Recruiting, Sponsor: Altor Bioscience Corporation
N=27 --> 54 | Initiation date: Oct 2016 --> May 2017 Trial primary completion date: Jan 2017 --> Jun 2017
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1 trial, Metastases: IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer (clinicaltrials.gov) - Feb 16, 2017
P1, N=28, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- Anktiva (inbakicept) / ImmunityBio
Trial initiation date: Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT (clinicaltrials.gov) - Feb 15, 2017
P2, N=60, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Jan 2017 --> Jun 2017 Initiation date: Jan 2017 --> Apr 2017
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P2 trial: QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML (clinicaltrials.gov) - Feb 10, 2017
P2, N=24, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment open: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - Feb 3, 2017
P2, N=60, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: Jan 2017 --> Apr 2017 Not yet recruiting --> Recruiting
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial primary completion date, Metastases: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 24, 2017
P1, N=20, Recruiting, Sponsor: Altor Bioscience Corporation
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Jul 2017
- |||||||||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P2/3 trial, Combination therapy: QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Jan 18, 2017
P2/3, N=80, Not yet recruiting, Sponsor: Altor Bioscience Corporation
- Empliciti (elotuzumab) / AbbVie, BMS
New P2 trial: 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) (clinicaltrials.gov) - Dec 27, 2016
P2, N=10, Not yet recruiting, Sponsor: University of Arkansas
- || Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial primary completion date, IO biomarker: QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 14, 2016
P1/2, N=57, Recruiting, Sponsor: Altor Bioscience Corporation
Trial primary completion date: Oct 2016 --> Jul 2017 Trial primary completion date: Oct 2016 --> Jan 2017
- CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment change, Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Dec 12, 2016
P1, N=48, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Oct 2016 --> Jan 2017 Trial primary completion date: Dec 2016 --> Mar 2017 | N=24 --> 48
- Anktiva (inbakicept) / ImmunityBio
Trial primary completion date: ALT-803: Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People (clinicaltrials.gov) - Dec 1, 2016
P1, N=10, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Dec 2016 --> Mar 2017 | N=24 --> 48 Trial primary completion date: Oct 2016 --> Mar 2017